DEVELOPMENT OF A METHOD FOR THE SYNTHESIS OF CPG-OLIGONUCLEOTIDES PROMISING FOR IMMUNOTHERAPY OF CANCER
Abstract and keywords
Abstract (English):
This article describes a new method for the synthesis of 2`-O-methoxymethyl monomers applicable for the efficient automated synthesis of 2`-O-modified oligoribonucleotides used for immunotherapy of oncological diseases localized in the gastrointestinal tract.

Keywords:
CpG oligonucleotides, oligoribonucleotides, immunotherapy, oncology
Text
Publication text (PDF): Read Download
References

1. Berglof A., Turunen J.J., Gissberg O., Bestas B., Blomberg K.E., Smith S.I. Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Rev. Clin. Immunol. 2013. Vol. 9 (12). P. 1205-1221. DOI:https://doi.org/10.1586/1744666X.2013.850030.

2. Yue X., Q. J. He Chen. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020. Vol. 20:524. DOI:https://doi.org/10.1186/s12935-020-01614-z.

3. Ben-Ali M., Kechout N., Mekki N., et al. Barbouche Genetic Approaches for Definitive Diagnosis of Agammaglobulinemia in Consanguineous Families. J. Clin. Immunol. 2020. Vol. 40(1). P. 96-104. DOI:https://doi.org/10.1007/s10875-019-00706-4. 6.

4. Nijman I.J., Montfrans van J.M., Hoogstraat M., et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J. Allergy Clin. Immunol. 2014. Vol. 133(2). P. 529-534. DOI:https://doi.org/10.1016/j.jaci.2013.08.032.

5. Kanegane H., Hoshino A., Okano T., et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol. Int. 2018. Vol. 67(1). P. 43-54. DOI:https://doi.org/10.1016/j.alit.2017.06.003.

6. Dengjel J., Kratchmarova I., Blagoev B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst. 2009. Vol. 5. № 10. P. 1112-1121. DOI: https://doi.org/10.1039/B909534A.

7. Mohamed A.J., Yu L., Bäckesjö C.M., Vargas L., Faryal R., Aints A., Christensson B., Berglöf A., Vihinen M., Nore B.F., Smith C.I. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domainyu. Immunol. Rev. 2009. Vol. 228. №. 1. P. 114-131. DOI: https://doi.org/10.1007/978-3-319-22714-6_5.

8. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011. Vol. 117. № 23. P. 6287-6296. DOI:https://doi.org/10.1182/blood-2011-01-328484.

9. Bernard S., Danglade D., Gardano L., et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int. Journal of Cancer. 2015. Vol. 136. № 12. P. 2761-2774. DOI: https://doi.org/10.1007/978-3-319-18257-5_24.

10. Robak T., Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int. Rev. Immunol. 2013. Vol. 32(4). P. 358-376. DOI:https://doi.org/10.3109/08830185.2013.786711.

Login or Create
* Forgot password?